CORESTEMCHEMON Inc. (KOSDAQ:166480)
South Korea
· Delayed Price · Currency is KRW 3,265.00
+70.00 (2.19%)
At close: Apr 28, 2026
CORESTEMCHEMON Revenue
In the year 2025, CORESTEMCHEMON had annual revenue of 20.16B KRW, down -29.91%. CORESTEMCHEMON had revenue of 4.95B in the quarter ending December 31, 2025, with 0.59% growth.
Revenue
20.16B
Revenue Growth
-29.91%
P/S Ratio
7.18
Revenue / Employee
559.97M
Employees
36
Market Cap
144.84B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 20.16B | -8.60B | -29.91% |
| Dec 31, 2024 | 28.76B | -4.89B | -14.54% |
| Dec 31, 2023 | 33.66B | -12.22B | -26.64% |
| Dec 31, 2022 | 45.88B | 15.64B | 51.71% |
| Dec 31, 2021 | 30.24B | 3.88B | 14.73% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BIO-FD&C | 19.18B |
| QuadMedicine | 10.70B |
| NovMetaPharma | 1.30B |
| Cell Biotech | 53.13B |
| Ensol Biosciences | 537.46M |
| Prestige Biologics | 19.24B |
| KoBioLabs | 69.29B |
| CHA Vaccine Research Institute | 158.62M |